Arye Hasson - Kadimastem Executive Vice President-Research & Development
| KDST Stock | ILA 1,189 14.00 1.19% |
President
Dr. Arye Hasson serves as Executive Vice President Research Development at Kadimastem Ltd since May 2012. Until this date, he served as Vice President Research Development at the Company from September 15, 2009. His work experience includes the following roles Head of Stem Cell, Diabetic and Neurological Projects at Gamida Cell Ltd since 2012.
| Age | 53 |
| Tenure | 12 years |
| Phone | 972 73 797 1600 |
| Web | https://www.kadimastem.com |
Kadimastem Management Efficiency
The company has return on total asset (ROA) of (0.7485) % which means that it has lost $0.7485 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (7.3543) %, meaning that it generated substantial loss on money invested by shareholders. Kadimastem's management efficiency ratios could be used to measure how well Kadimastem manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Gary Saunders | Tower Semiconductor | 54 | |
| Yossi Netzer | Tower Semiconductor | 59 | |
| Itzhak Edrei | Tower Semiconductor | 58 | |
| Mark Sabag | Teva Pharmaceutical Industries | 52 | |
| Avi Strum | Tower Semiconductor | 61 | |
| Yuval Ramon | Elbit Systems | 57 | |
| Eliyahu Kalif | Teva Pharmaceutical Industries | 50 | |
| Oren Shirazi | Tower Semiconductor | 53 | |
| Yehuda Vered | Elbit Systems | 65 | |
| Yoram Shmuely | Elbit Systems | 62 | |
| Avi Mizrachi | Elbit Systems | 60 | |
| Hafrun Fridriksdottir | Teva Pharmaceutical Industries | 57 | |
| Kevin Mannix | Teva Pharmaceutical Industries | N/A | |
| Nati Somekh | Tower Semiconductor | 48 | |
| Shelly Gordon | Elbit Systems | 58 | |
| Edgar Maimon | Elbit Systems | 64 | |
| Ilan Pacholder | Elbit Systems | 64 | |
| Ran Kril | Elbit Systems | 52 | |
| Ilan Rabinovich | Tower Semiconductor | 61 | |
| Akhtar Ashfaq | Opko Health | N/A | |
| Sven Dethlefs | Teva Pharmaceutical Industries | 54 | |
Management Performance
| Return On Equity | -7.35 | |||
| Return On Asset | -0.75 |
Kadimastem Leadership Team
Elected by the shareholders, the Kadimastem's board of directors comprises two types of representatives: Kadimastem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kadimastem. The board's role is to monitor Kadimastem's management team and ensure that shareholders' interests are well served. Kadimastem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kadimastem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Keren Tzlill, External Director | ||
| Yossi Nizhar, Vice President - Finance | ||
| Ilan Hadar, External Director | ||
| Arik Hasson, Exec Devel | ||
| Yossi BenYossef, Honorary Consultant | ||
| Michal Izrael, VP Diseases | ||
| David Sultan, Independent Director | ||
| Asaf Shiloni, Chief Officer | ||
| Michel Revel, Chief Scientific Officer-Services Provider, Director | ||
| Ram Epstein, Chief Executive Officer, Director | ||
| Joseph Eldor, Director | ||
| Michal Harel, Vice President - Research & Development-ALS & Neurodegenerative Diseases | ||
| Pr MD, Chief CoFounder | ||
| Abraham Meizler, Director | ||
| Eli Opper, Chairman of the Board | ||
| Ziv Ironi, External Director | ||
| Neta Lavon, Vice President - Operations | ||
| Julien Ruggieri, Director | ||
| Arye Hasson, Executive Vice President-Research & Development |
Kadimastem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kadimastem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.35 | |||
| Return On Asset | -0.75 | |||
| Current Valuation | 38.77 M | |||
| Shares Outstanding | 35.76 M | |||
| Shares Owned By Insiders | 53.72 % | |||
| Shares Owned By Institutions | 8.31 % | |||
| Price To Earning | (167.60) X | |||
| Price To Book | 5.90 X | |||
| EBITDA | (24.48 M) | |||
| Net Income | (26.27 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Kadimastem Stock
Kadimastem financial ratios help investors to determine whether Kadimastem Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kadimastem with respect to the benefits of owning Kadimastem security.